Apic Bio, a privately held developer of gene therapies for rare disorders, has agreed to sell the rights to one of its experimental ALS treatments to the biotechnology company UniQure in a deal announced Tuesday.
Per deal terms, UniQure will pay $10 million up front for worldwide rights to the treatment, which was called APB-102 but will now be known as AMT-162. Apic could later be eligible for up to $45 million in additional payments should its therapy secure approval in the U.S. and Europe and hit certain sales goals.
